1. Effects of Iron Chelation in Osteosarcoma
- Author
-
Daniela Di Pinto, Alessandra Di Paola, Chiara Tortora, Maura Argenziano, Silverio Perrotta, Martina Di Martino, Elvira Pota, Francesca Rossi, Francesca Punzo, Argenziano, Maura, Di Paola, Alessandra, Tortora, Chiara, Di Pinto, Daniela, Pota, Elvira, Di Martino, Martina, Perrotta, Silverio, Rossi, Francesca, and Punzo, Francesca
- Subjects
Cancer Research ,MG63 ,Cell Survival ,Eltrombopag ,Apoptosis ,Bone Neoplasms ,Iron Chelating Agents ,Benzoates ,chemistry.chemical_compound ,Cell Line, Tumor ,Drug Discovery ,medicine ,Humans ,Cell Proliferation ,Pharmacology ,Osteosarcoma ,Tumor microenvironment ,Chemistry ,Cell Cycle ,Deferasirox ,Cancer ,medicine.disease ,Iron Chelation ,143B ,Hydrazines ,Treatment Outcome ,Oncology ,Tumor progression ,Cancer cell ,Cancer research ,Pyrazoles ,Drug Therapy, Combination ,medicine.drug - Abstract
Background: Osteosarcoma is an aggressive bone tumor. Itrepresents the principal cause of cancer-associated death in children.Considering the recent findings on the role of iron in cancer, iron chelation has been investigated for its antineoplastic properties in many tumors. Deferasirox is the most used iron chelator compound and in previous studies showed an anticancer effectinhematologic and solid malignancies. Eltrombopag is a Thrombopoietin receptor used in thrombocytopenia, that also binds and mobilize iron. It demonstrated an effect in iron overload conditions and also in contrasting cancer cells proliferation. Objective: We analyzed the effects of Deferasirox and Eltrombopag in Human Osteosarcoma cells, in the attempt to identify other therapeutic approaches for this tumor. Methods: We cultured and treated withDeferasirox and Eltrombopag, alone and in combination, two human osteosarcoma cell lines, MG63 and 143B. After 72h exposure, we performed RTqPCR, Western Blotting, Iron Assay and cytofluorimetric assays to evaluate the effect on viability, apoptosis, cell cycle progression and ROS production. Results: The iron chelating properties of the two compounds are confirmed also in Osteosarcoma, but we did not observe any direct effect on tumor progression. Discussion: We tested Deferasirox and Eltrombopag, alone and in combination, in Human Osteosarcoma cells for the first time and demonstrated that their iron chelating activity does not influence biochemical pathways related to cancer progression and maintenance. Conclusion: Although further investigations on possible effects mediated by cells of the tumor microenvironment could be of great interest, in vitro iron chelation in Osteosarcoma does not impair tumor progression.
- Published
- 2021
- Full Text
- View/download PDF